GlaxoSmithKline (LON:GSK) share price: what to expect from its Q1 results
The pharmaceutical company recorded a strong 2018, with the company wasting no time in driving growth this year with investors eager for an update on its acquisition of Tesaro and its consumer health joint venture with Pfizer.
When is GlaxoSmithKline’s results date?
GlaxoSmithKline (GSK) will release its Q1 trading update on May 1.
GlaxoSmithKline results preview: what does the city expect?
At the end of what was a very successful 2018, GSK announced it would form a new world-leading consumer healthcare joint venture (JV) with rival Pfizer in a move that will see its combined businesses generate sales of around £9.8 billion.
Under the terms of the deal, GSK controls a 68% majority stake in the JV, with the transaction representing a major opportunity for the pharmaceutical company to build on its recent buyout of Novartis that will help it deliver significant shareholder value.
Investors will welcome an update on the JV, which brings together two highly complementary portfolios of consumer health brands, including GSK’s Sensodyne, Voltaren, and Panadol, alongside Pfizer’s Advil, Centrum and Caltrate.
The deal will also see the newly formed business become a global leader I over-the-counter products with a market share of 7.3% ahead of its nearest rival and allow it to grab the number one or two position in all major geographies, including the US and China. Overall the Joint Venture will target an Adjusted operating margin percentage in the ‘mid-to-high 20’s’ by 2022.
Investors will have their eye on what GSK intends to pay in dividends to shareholders for 2019, with the JV allowing them to confirm an 80p a share payout, which its management intends to maintain.
In January, GSK completed its acquisition of oncology focused biopharmaceutical company Tesaro in a deal valued at £4 billion that will strengthen its pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology.
‘The acquisition of Tesaro, which we have completed today, significantly strengthens our oncology pipeline and brings new scientific capabilities and expertise that will increase the pace and scale at which we can help patients living with cancer,’ GSK Chief Scientific Officer and President Dr Hal Barron said.
Overall, investors are expecting another strong year from GSK, with analysts arguing that the stock is undervalued. Zacks Equity Research gave the stock a ‘Buy’ rating, pointing to the fact that GSK is trading with price/earnings (P/E) ratio of 13.51, compared to an industry average of 14.37. Over the past 52 weeks, GSK’s forward P/E has hit as high as 14.65 and as low as 12.29, with a median of 13.59.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
European Central Bank meeting
Learn about how the ECB meeting affects interest rates and price stability ahead of the next announcement on 24 October 2019.
- How might the next meeting affect the markets?
- What are the key rate decisions to watch?
- Why is the Governing Council announcement important for traders?
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.